Harry G. Heijerman, MD; Cornelis B. Lamers, MD; Willem Bakker, MD
Heijerman HG, Lamers CB, Bakker W. Omeprazole Enhances the Efficacy of Pancreatin (Pancrease) in Cystic Fibrosis. Ann Intern Med. 1991;114:200-201. doi: 10.7326/0003-4819-114-3-200
Download citation file:
Published: Ann Intern Med. 1991;114(3):200-201.
We studied the effect of the addition of omeprazole (20 mg once a day) to treatment with pancreatin (Pancrease, Cilag, Herentals, Belgium), two or four capsules three times a day, on fecal fat excretion in a double-blind, crossover fashion in nine patients with cystic fibrosis having persistent steatorrhea while taking Pancrease, two capsules three times a day (mean fecal fat excretion, 22.3%; range, 12% to 44%). Neither doubling of the dose of Pancrease nor addition of omeprazole to the lower dose of Pancrease significantly reduced fecal fat excretion (mean, 19.6% [range, 10% to 34%]; mean, 16.4% [range, 6% to 32%], respectively). However, addition of omeprazole to the higher dose of Pancrease (four capsules three times a day) significantly reduced fecal fat excretion when compared with the two doses of Pancrease alone (mean, 10.7%; range, 4% to 25%; P < 0.01). We conclude that adjunct therapy with omeprazole reduces fecal fat excretion in cystic fibrosis provided that a high dose of Pancrease is supplied.
Learn more about subscription options.
Register Now for a free account.
Gastroenterology/Hepatology, Pulmonary/Critical Care, Pancreatic Disease.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only